Consensus UCB SA Wiener Boerse

Stocks

UCB

BE0003739530

Pharmaceuticals

End-of-day quote Wiener Boerse 2026-09-10			5-day change	1st Jan Change
200.90 ^EUR	-1.57%		-6.12%	-15.37%

09-11	AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up	MT
09-10	UCB: A rare window of affordability

Evolution of the Average Target: UCB SA

Data source: UCB(UCB)

Evolution of the Target Price: UCB SA

Data source: UCB(UCB)

Changes in Analyst Recommendations: UCB SA

Data source: UCB(UCB)

b009.w0OOn4AQtnmhGbfthCJJYLnPc25D_XczSbW6o_dtZic.lBfPqtpl5hLnS4Xd6EodOeuZNhwPsEZlJMPp55I3MFGsB8rp5FHVFfBO2A~73109c8c0cb781240acc6e26c52c2f66

Analysts' recommendations: UCB SA

09-11	AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up	MT
09-10	UCB: A rare window of affordability
08-20	Cancer vaccines finally garner the spotlight
08-18	UCB: An unimpressive upgrade-led correction opens a rare opportunity
08-11	Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed	MT
08-11	UCB barely moves despite positive calls from ING and Berenberg
07-31	AlphaValue/Baader Europe Upgrades UCB to Add, Trims PT	MT
07-30	Kempen Upgrades UCB to Buy Rating, Boosts PT	MT
07-14	Where would AI lead Pharma in the long run?
07-03	Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals	MT
06-22	UBS Trims UCB's PT, Affirms Buy Rating	MT
06-15	UCB Slumps Following Analyst Downgrade
06-15	Barclays Downgrades UCB to Equalweight, Trims PT	MT
06-15	UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum	MT
06-09	UCB Favored by Oddo BHF
06-05	KBC Securities Maintains Buy Rating on UCB
05-21	UCB Price Target, Estimates Up as AlphaValue/Baader Europe Notes Growth Momentum	MT
05-20	UCB: Executing well, but valuation lacks safety net
04-27	AlphaValue/Baader Europe Upgrades UCB to Reduce, Trims PT	MT
03-30	MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says	MT
03-16	Berenberg says Belgian drugmaker UCB stock is undervalued
03-16	Berenberg Keeps UCB Amid Positive Pipeline Progress, H2 Catalysts	MT
02-26	UCB: H2 beat; 2026 outlook healthy; but valuation remains red-hot
02-24	Wolfe Research Kicks Off UCB Coverage at Outperform	MT
02-02	UCB on Track for 'Impressive' Growth Acceleration, Says RBC	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REGENERON PHARMACEUTICALS, INC.					+7.07%
	CSL LIMITED					+1.38%
	MODERNA, INC.					-14.73%
	SAMSUNG BIOLOGICS CO.,LTD.					+38.27%
	UCB					+41.3%
	BIOGEN INC.					+10.1%
	INCYTE CORPORATION					+3.62%
	INNOVENT BIOLOGICS, INC.					+36.27%
	SWEDISH ORPHAN BIOVITRUM AB					+14.16%
	Average					+15.27%
	Weighted average by Cap.					+13.05%